Repeated administration of hepatitis C virus core-encoding plasmid to mice does not necessarily increase the immune response generated against this antigen

被引:5
作者
Dueñas-Carrera, S
Alvarez-Lajonchere, L
Alvarez, JC
Ramos, T
Pichardo, D
Morales, J
机构
[1] Ctr Ingn Genet & Biotecnol, Vaccine Div, HCV Dept, Havana, Cuba
[2] Ctr Nacl Genet Med, Havana, Cuba
关键词
genetic immunization; HCV; lymphocyte proliferation; nucleocapsid; vaccine;
D O I
10.1042/BA20000076
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA immunization is a promising approach in generating immune responses to infectious pathogens in many different animal models. In an effort to augment the anti-[hepatitis C virus (HCV) core] immune response, generated after DNA immunization, the importance of vaccination regimen regarding dose and boosting was investigated in the present study. Balb/c mice were intramuscularly injected with an expression plasmid encoding a truncated variant comprising amino acids 1-176 of the HCV core protein. The highest anti-core antibody titres (1:3700) were detected in mice inoculated with 50-100 mug of core-encoding plasmid. Additionally, we demonstrated that antibody levels induced by a single injection of DNA could be further increased by boosting with a second injection of DNA three weeks after primary immunization. However, administration of additional doses or lengthening of the resting period between inoculations resulted in similar or even weaker anti-core antibody responses. A similar anti-(HCV core) lymphoproliferative response was also detected in animals that had the highest level of anti-core antibodies. These results indicate that, in clinical trials, vaccination regimen might be a critical factor in generating optimal anti-(HCV core) immune responses after genetic immunization.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 20 条
[1]  
CHEN Z, 1995, VACCINE RES, V4, P135
[2]   DNA-mediated immunization to hepatitis B surface antigen: Longevity of primary response and effect of boost [J].
Davis, HL ;
Mancini, M ;
Michel, ML ;
Whalen, RG .
VACCINE, 1996, 14 (09) :910-915
[3]   DNA vaccines [J].
Donnelly, JJ ;
Ulmer, JB ;
Shiver, JW ;
Liu, MA .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :617-648
[4]   A truncated variant of the hepatitis C virus core induces a slow but potent immune response in mice following DNA immunization [J].
Dueñas-Carrera, S ;
Alvarez-Lajonchere, L ;
Alvarez-Obregón, JC ;
Herrera, A ;
Lorenzo, LJ ;
Pichardo, D ;
Morales, J .
VACCINE, 2000, 19 (7-8) :992-997
[5]  
Duenas-Carrera Santiago, 1999, Biotecnologia Aplicada, V16, P226
[6]  
Encke J, 1998, J IMMUNOL, V161, P4917
[7]   Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization [J].
Fournillier, A ;
Depla, E ;
Karayiannis, P ;
Vidalin, O ;
Maertens, G ;
Trépo, C ;
Inchauspé, G .
JOURNAL OF VIROLOGY, 1999, 73 (09) :7497-7504
[8]   Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes [J].
Fournillier, A ;
Nakano, I ;
Vitvitski, L ;
Defla, E ;
Vidalin, O ;
Maertens, G ;
Trépo, C ;
Inchauspé, G .
HEPATOLOGY, 1998, 28 (01) :237-244
[9]   CANCER GENE-THERAPY USING PLASMID DNA - PURIFICATION OF DNA FOR HUMAN CLINICAL-TRIALS [J].
HORN, NA ;
MEEK, JA ;
BUDAHAZI, G ;
MARQUET, M .
HUMAN GENE THERAPY, 1995, 6 (05) :565-573
[10]   Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization [J].
Hu, GJ ;
Wang, RYH ;
Han, DS ;
Alter, HJ ;
Shih, JWK .
VACCINE, 1999, 17 (23-24) :3160-3170